Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation (symbol: BLCO) is a prominent player in the vision care industry based in Madrid, Spain. Originally part of Bausch Health, Bausch + Lomb became a public company in 2022. It operates in three primary segments: vision care, surgical, and ophthalmic pharmaceuticals.
Vision Care Segment: This segment covers contact lenses and ocular health products. Bausch + Lomb holds a 10% market share in contact lenses, and its portfolio includes popular brands such as Biotrue and Lumify.
Surgical Segment: This includes intraocular lenses and equipment for cataract and vitreoretinal surgeries. The company also provides a range of surgical instruments, making it a comprehensive provider in the surgical eye care market.
Ophthalmic Pharmaceuticals: Bausch + Lomb offers over 100 products, including Xipere, Vyzulta, and Lotemax, which are designed to treat various eye conditions. This extensive lineup makes Bausch + Lomb a leader in the ophthalmic pharmaceuticals market.
With a strong commitment to innovation and quality, Bausch + Lomb continuously works on new projects and partnerships to enhance its product offerings. The company’s diverse portfolio and strategic initiatives ensure its significant role in the vision care industry.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has announced 25 presentations during the upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego from May 5-8, 2023. This includes 21 podium presentations and four poster presentations, with highlights on the new StableVisc™ device and the LOTEMAX® ophthalmic gel. Bausch + Lomb will also sponsor two educational events focusing on dry eye disease and the IC-8 Apthera lens. Approximately 18 million Americans are affected by dry eye disease, emphasizing the significance of the topics discussed. Notably, new data from the ARMOR study will be presented, aiming to address antibiotic resistance in ocular microorganisms.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) held its 2023 annual meeting on April 24, 2023, where shareholders elected 10 directors. Key voting results included:
- Nathalie Bernier: 344,100,848 votes for, 124,733 against
- Richard U. De Schutter: 344,094,979 votes for, 130,602 against
- Gary Hu: 344,016,782 votes for, 208,799 against
- Brett Icahn: 344,072,707 votes for, 152,874 against
In addition to the elections, shareholders approved the advisory compensation of executives, an amendment to increase shares under the 2022 Omnibus Incentive Plan, and appointed PricewaterhouseCoopers LLP as the independent accounting firm until the 2024 annual meeting. The results will be filed with the SEC.
Bausch + Lomb Corporation has launched two new ophthalmic viscosurgical devices (OVDs), StableVisc and TotalVisc, aimed at enhancing cataract surgery outcomes. These devices provide dual-action protection, addressing concerns about free radical damage during surgical procedures. StableVisc maintains anterior chamber space, while TotalVisc combines both StableVisc and ClearVisc for comprehensive ocular protection.
With a fill volume of one milliliter, StableVisc leads its segment, reducing the need for multiple packs during surgery. The devices contain sodium hyaluronate and sorbitol, offering a strong barrier against free radicals, which can lead to post-surgical complications.
This launch positions Bausch + Lomb as a leader in innovative solutions for eye health, particularly in the competitive cataract surgery market.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced eight scientific poster presentations at the ARVO annual meeting in New Orleans from April 23-27, 2023. Highlights include results from the 12-month KALAHARI safety extension study of NOV03 (perfluorohexyloctane) and data on XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use. Notable studies presented include antibiotic resistance patterns from the ARMOR surveillance study and evaluations on intraocular lens pipeline programs. Bausch + Lomb remains committed to advancing research and innovation in eye health to meet patient needs.
Bausch + Lomb Corporation (BLCO) has announced significant achievements in its eye care recycling initiatives. The ONE by ONE and Biotrue® Eye Care Recycling programs have successfully recycled a total of 65.8 million units, equivalent to 397,194 pounds of waste, since their inception. The ONE by ONE program, launched in 2016, has collected over 65 million used contact lenses and related materials, while the Biotrue® program, initiated in 2021, has gathered more than 440,000 eye drop units and lens cases. With nearly 13,000 eye care practices participating, these programs aim to mitigate plastic waste and contribute to sustainability efforts. Bausch + Lomb collaborates with TerraCycle for recycling operations, emphasizing their commitment to environmental health.
FAQ
What is the current stock price of Bausch + Lomb Corporation (BLCO)?
What is the market cap of Bausch + Lomb Corporation (BLCO)?
What does Bausch + Lomb Corporation do?
When did Bausch + Lomb become a public company?
What are the primary segments Bausch + Lomb operates in?
What are some key products in Bausch + Lomb's vision care segment?
What does Bausch + Lomb offer in its surgical segment?
What products are included in Bausch + Lomb's ophthalmic pharmaceuticals segment?
Where is Bausch + Lomb Corporation headquartered?
What market share does Bausch + Lomb hold in the contact lenses market?
What makes Bausch + Lomb a leader in the ophthalmic pharmaceuticals market?
What is Bausch + Lomb's commitment towards its products and services?
